Mezzion Pharma Co.,Ltd.

A140410

KR7140410002

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 03:30:00 11/06/2024 am IST			5-day change	1st Jan Change
42,050 ^KRW	+3.83%		+6.19%	+7.82%

14/05	Mezzion Pharma Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
18/03	Mezzion Pharma Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Mezzion Pharma Co. Ltd. Appoints Jefferson Gregory to its Board of Directors

October 09, 2014 at 06:29 pm IST

Mezzion Pharma Co. Ltd. announced appointment of Jefferson Gregory, B.S. Pharm., J.D., HD to the company's Board of Directors. He is currently the Chairman and CEO of Rockward Pharmaceuticals and Rockward Pharmaceutical Consultants, LLC.

Latest news about Mezzion Pharma Co.,Ltd.

Mezzion Pharma Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
Mezzion Pharma Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03	CI
Mezzion Pharma Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Mezzion Pharma Co.,Ltd. announced that it has received KRW 49.99999719 billion in funding from BRV Capital Management and other investors	20/23/20	CI
Mezzion Pharma Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
Mezzion Pharma to Raise 50 Billion Won From Share Sale	20/23/20	MT
Mezzion Pharma Co.,Ltd. announced that it expects to receive KRW 49.99999719 billion in funding from BRV Capital Management	19/23/19	CI
Mezzion Pharma Co.,Ltd. Submits Protocol for Confirmatory Pivotal Phase 3 Trial ("FUEL-2") in Fontan Subjects	21/23/21	CI
Mezzion Pharma Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11/22/11	CI
Mezzion Pharma Co.,Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/22/12	CI
Mezzion Pharma Co.,Ltd. Receives Clear FDA Path Forward for the Approval of Udenafil for Single Ventricle Heart Disease	31/22/31	CI
Mezzion Pharma Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	11/22/11	CI
Mezzion Pharma Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	23/22/23	CI
Mezzion Pharma Announces Positive Data Presented to FDA in Type C Meeting	21/21/21	CI
Mezzion Pharma Co.,Ltd. announced that it has received KRW 20 billion in funding	16/21/16	CI
Mezzion Pharma Co.,Ltd. announced that it expects to receive KRW 20 billion in funding	12/21/12	CI
Mezzion Appoints William Breitenbach as Chief Commercial Officer for Mezzion's Global Commercial Operations	15/21/15	CI
Mezzion's New Drug Application for Its Orphan Drug Udenafil for the Treatment of Single Ventricle Heart Disease Has Been Accepted for Filing by the FDA	26/21/26	CI
Mezzion Pharma Co. Ltd. Announces Re-Submission of New Drug Application for its Orphan Drug Udenafil	29/21/29	CI
Mezzion Pharma Co. Ltd. Announces Submission of New Drug Application for its Orphan Drug Udenafil to Treat Patients	30/20/30	CI
Mezzion Pharma's Announces Results from the Pivotal 400-Subject Phase 3 Fuel Trial	19/20/19	CI
Mezzion Pharma Announces the Presentation of the FUEL Trial Data at the American Heart Association Meeting in Philadelphia	17/19/17	CI
Mezzion Pharma Co.,Ltd. Announces Top Line Data from FUEL Will Be Presented at the American Heart Association, Late Breaking Scientific Sessions, in Philadelphia, PA, November 17, 2019	04/19/04	CI
Mezzion Pharma Co.,Ltd. Announces Positive Results from the Fontan Udenafil Exercise Longitudinal Trial, in Adolescents with Single Ventricle Heart Disease Who Have Undergone the Fontan Procedure	31/19/31	CI
Mezzion Pharma Co.,Ltd. announced that it has received KRW 15 billion in funding from a group of investors	05/16/05	CI

Chart Mezzion Pharma Co.,Ltd.

Duration

Period

More charts

Company Profile

Mezzion Pharma Co., Ltd. is a Korea-based company engaged in the pharmaceutical business. The Company focuses on development and manufacture of remedies for erectile dysfunction and benign prostatic hyperplasia. In addition, the Company engages in the development of remedies for portal hypertension (PH), pulmonary arterial hypertension (PAH), overactive bladder (OAB), chronic obstructive pulmonary disease (COPD) and others. The Company has sighed licensing contract with overseas partners, including Warner in America, Valenta in Russia, Nycomed in Mexico and Dr.Falk in Europe. On April 22, 2013, the Company changed its name from Dong-A Pharmtech Co., Ltd. to Mezzion Pharma Co., Ltd.

Sector

Pharmaceuticals

Calendar

13/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
MEZZION PHARMA CO.,LTD.	+7.82%	877M
MERCK KGAA	+19.22%	80.29B
KYOWA KIRIN CO. LTD.	+15.04%	9.2B
SK BIOPHARMACEUTICALS CO., LTD.	-20.02%	4.67B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+49.11%	4.49B
YUHAN CORPORATION	+10.17%	4.27B
INDIVIOR PLC	+10.55%	2.25B
BETTA PHARMACEUTICALS CO., LTD.	-25.97%	2.13B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+16.34%	2.1B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-40.85%	1.78B